Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01817400 · ClinicalTrials.gov registry record · Early Phase 1
Mediators of Abnormal Reproductive Function in Obesity (MARO)
A Early Phase 1 study of Obesity and Infertility, Female, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01817400 is a Early Phase 1 study of Obesity and Infertility, Female that has completed, run by University of Colorado, Denver. The registered enrollment target is 10 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01817400, a Early Phase 1 study of Obesity and Infertility, Female, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is seeking to understand how being overweight and obese makes women less fertile. The studies the investigators have done so far indicate that there is a hormone or other substance produced by fat that goes into the blood and reduces reproductive hormones in women who are overweight and obese. The present study will try to find the most promising substances by studying small numbers of women and trying to remove the substances that are causing the problem. Hypothesis: A circulating factor or factors, either hormonal, inflammatory or metabolic, causes relative pituitary hypofunction and correction of this reproductive deficit will allow obese women with infertility who have failed to reduce their body weight to normal to conceive, and may also prevent the horizontal passage of an adverse metabolic phenotype to the offspring.
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Pioglitazone
- OTHER Microdialysis
- DIETARY_SUPPLEMENT Vascepa - Fish Oil
Study Locations (1)
Colorado
- University of Colorado Denver Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01817400
The ClinicalTrials.gov registry entry for NCT01817400 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Aspirin is the first listed.
NCT01817400 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01817400 about?
NCT01817400 is a clinical study titled "Mediators of Abnormal Reproductive Function in Obesity (MARO)". The study is seeking to understand how being overweight and obese makes women less fertile. The studies the investigators have done so far indicate that there is a hormone or other substance produced by fat that goes into the blood and reduces reproductive hormones in women who are overweight and ob...
What is the current status of trial NCT01817400?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2013-03. Estimated completion is 2014-12.
What conditions does trial NCT01817400 study?
This clinical trial studies the following conditions: Obesity, Infertility, Female.
What interventions are being tested in trial NCT01817400?
The interventions under investigation include: Aspirin (DRUG), Pioglitazone (DRUG), Microdialysis (OTHER), Vascepa - Fish Oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01817400?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01817400 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Social Determinants of Sleep and Obesity
RECRUITING · Early Phase 1
-
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.